Abstract:Key PointsThe Hedgehog signalling pathway has diverse functions in animal development and tissue homeostasis. Dysregulation of the pathway has been implicated in several developmental syndromes and cancers.The production of Hedgehog (HH) ligands involves autoproteolytic cleavage and the addition of lipid moieties such as cholesterol and palmitic acid. Several dedicated proteins are required for the secretion of the ligand.Novel mechanisms involving ligand multimerization, complex formation with additional soluble proteins and association with components of the extracellular matrix, such as the heparan sulphate proteoglycans, have been proposed to explain the dispersion of lipidated HH proteins through tissues.Signal transduction requires a number of transmembrane proteins, most notably Patched 1 (PTC) and Smoothened (SMO). The mechanism by which the signal is transduced from PTC to SMO is unclear. Strikingly, in vertebrates, but not Drosophila melanogaster, signal transduction requires the primary cilia of cells, identifying a function for this previously enigmatic organelle.Intracellularly, signalling involves Suppressor of Fu (SUFU), the kinesin proteins Costal 2 (Cos2) in D. melanogaster and KIF7 in vertebrates and several kinases. Signalling culminates with the regulation of the D. melanogaster Cubitus interruptus (Ci) and vertebrate GLI families of transcription factors. HH signalling converts the Ci and GLI proteins from transcriptional repressors to activators by inhibiting their proteolytic cleavage.The various functions of HH signalling have predominately been ascribed to its regulation of gene expression, and the relevant transcriptional networks are beginning to be dissected. Recently, however, non-canonical branches to the signalling pathway have been found, and these might contribute to some HH functions.HH signalling regulates the survival and proliferation of tissue progenitor and stem populations. This function is linked to its role in tumour formation. Several small-molecule antagonists and agonists that target SMO have been identified, and these show promise in the treatment of HH-related pathologies. In 2012, the approval of the Food and Drug Administration (FDA) was obtained for the first drug that targets HH signalling in the skin cancer basal cell carcinoma.

Proteinmodifications in Hedgehog Signaling Cross Talk and Feedback Regulation Confer Divergent Hedgehog Signaling Activity

Protein Modifications in Hedgehog Signaling: Cross Talk and Feedback Regulation Confer Divergent Hedgehog Signaling Activity.

Protein Modifications in Hedgehog Signaling

Coupling of Hedgehog and Hippo Pathways Promotes Stem Cell Maintenance by Stimulating Proliferation

Recent Progress in the Study of Hedgehog Signaling

Regulation of Smoothened Phosphorylation and High-Level Hedgehog Signaling Activity by a Plasma Membrane Associated Kinase

Regulation of Hedgehog Signal Transduction by Ubiquitination and Deubiquitination

Hedgehog Signalling Activity of Smoothened Requires Phosphorylation by Protein Kinase A and Casein Kinase I

Hedgehog Regulates Smoothened Activity by Inducing a Conformational Switch

Mechanisms of Smoothened Regulation in Hedgehog Signaling

Transducing the Hedgehog Signal Across the Plasma Membrane

Current Status of Hedgehog Signaling Inhibitors

The mechanisms of Hedgehog signalling and its roles in development and disease

Casein Kinase 2 Promotes Hedgehog Signaling by Regulating Both Smoothened and Cubitus Interruptus

The interplay of Patched, Smoothened and cholesterol in Hedgehog signaling

Hedgehog Signaling in Tissue Homeostasis, Cancers, and Targeted Therapies.

Competition Between Two Phosphatases Fine-Tunes Hedgehog Signaling

Progress of Study on Hedgehog Signaling Pathway

The emerging roles of phosphatases in Hedgehog pathway

The Hedgehog Family and the Differentiation of Lymphocytes and Stem Cells

Clinical Research Progress of Hedgehog Signaling Path ways